Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217188991> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3217188991 abstract "Introduction: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C lowering agent with twice-yearly subcutaneous dosing (after the initial and 3-month doses). Aim: To analyze the efficacy and safety of inclisiran in patients with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalent across body mass index (BMI) strata. Methods: In this post hoc analysis from ORION-9 (NCT03397121), ORION-10 (NCT03399370) and ORION-11 (NCT03400800), eligible patients were randomized 1:1 to receive 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) or placebo at baseline, Day 90 and 6-monthly thereafter. Analyses were stratified by baseline BMI: <25, 25-<30, 30-<35 or ≥35 kg/m 2 . Percentage change in atherogenic lipids from baseline at Day 510 was evaluated. Safety was assessed over 540 days. Results: Baseline demographic and clinical characteristics including atherogenic lipid levels were mostly balanced between the treatment arms and across the BMI strata ( Table ). Percentage change in atherogenic lipids from baseline at Day 510 was significantly greater with inclisiran vs placebo within each BMI stratum ( Table ). Treatment-emergent adverse events (TEAE) and treatment-emergent serious adverse events were generally similar between the treatment arms and were reported more frequently with increasing BMI strata (data not shown). Clinically relevant TEAEs at the injection site were reported more frequently with inclisiran vs placebo similarly across strata, but all were mild or moderate. Conclusions: Twice-yearly dosing with inclisiran (after the initial and 3-month doses) provided effective and sustained lipid lowering in patients, irrespective of their baseline BMI, and was generally well tolerated." @default.
- W3217188991 created "2021-12-06" @default.
- W3217188991 creator A5005453947 @default.
- W3217188991 creator A5028480812 @default.
- W3217188991 creator A5044425699 @default.
- W3217188991 creator A5046728643 @default.
- W3217188991 creator A5065063579 @default.
- W3217188991 creator A5065943869 @default.
- W3217188991 creator A5075595313 @default.
- W3217188991 creator A5076770998 @default.
- W3217188991 creator A5080414941 @default.
- W3217188991 creator A5080753934 @default.
- W3217188991 date "2021-11-16" @default.
- W3217188991 modified "2023-09-23" @default.
- W3217188991 title "Abstract 11143: Efficacy and Safety of Inclisiran by Baseline Body Mass Index: A Post Hoc Pooled Analysis of the ORION-9, ORION-10 and ORION-11 Phase III Randomized Controlled Trials" @default.
- W3217188991 doi "https://doi.org/10.1161/circ.144.suppl_1.11143" @default.
- W3217188991 hasPublicationYear "2021" @default.
- W3217188991 type Work @default.
- W3217188991 sameAs 3217188991 @default.
- W3217188991 citedByCount "0" @default.
- W3217188991 crossrefType "journal-article" @default.
- W3217188991 hasAuthorship W3217188991A5005453947 @default.
- W3217188991 hasAuthorship W3217188991A5028480812 @default.
- W3217188991 hasAuthorship W3217188991A5044425699 @default.
- W3217188991 hasAuthorship W3217188991A5046728643 @default.
- W3217188991 hasAuthorship W3217188991A5065063579 @default.
- W3217188991 hasAuthorship W3217188991A5065943869 @default.
- W3217188991 hasAuthorship W3217188991A5075595313 @default.
- W3217188991 hasAuthorship W3217188991A5076770998 @default.
- W3217188991 hasAuthorship W3217188991A5080414941 @default.
- W3217188991 hasAuthorship W3217188991A5080753934 @default.
- W3217188991 hasConcept C126322002 @default.
- W3217188991 hasConcept C142724271 @default.
- W3217188991 hasConcept C168563851 @default.
- W3217188991 hasConcept C197934379 @default.
- W3217188991 hasConcept C204787440 @default.
- W3217188991 hasConcept C27081682 @default.
- W3217188991 hasConcept C2777288759 @default.
- W3217188991 hasConcept C2778096610 @default.
- W3217188991 hasConcept C2780221984 @default.
- W3217188991 hasConcept C511355011 @default.
- W3217188991 hasConcept C67761136 @default.
- W3217188991 hasConcept C71924100 @default.
- W3217188991 hasConceptScore W3217188991C126322002 @default.
- W3217188991 hasConceptScore W3217188991C142724271 @default.
- W3217188991 hasConceptScore W3217188991C168563851 @default.
- W3217188991 hasConceptScore W3217188991C197934379 @default.
- W3217188991 hasConceptScore W3217188991C204787440 @default.
- W3217188991 hasConceptScore W3217188991C27081682 @default.
- W3217188991 hasConceptScore W3217188991C2777288759 @default.
- W3217188991 hasConceptScore W3217188991C2778096610 @default.
- W3217188991 hasConceptScore W3217188991C2780221984 @default.
- W3217188991 hasConceptScore W3217188991C511355011 @default.
- W3217188991 hasConceptScore W3217188991C67761136 @default.
- W3217188991 hasConceptScore W3217188991C71924100 @default.
- W3217188991 hasIssue "Suppl_1" @default.
- W3217188991 hasLocation W32171889911 @default.
- W3217188991 hasOpenAccess W3217188991 @default.
- W3217188991 hasPrimaryLocation W32171889911 @default.
- W3217188991 hasRelatedWork W1966097884 @default.
- W3217188991 hasRelatedWork W2019671135 @default.
- W3217188991 hasRelatedWork W2100355815 @default.
- W3217188991 hasRelatedWork W2107187998 @default.
- W3217188991 hasRelatedWork W2186710565 @default.
- W3217188991 hasRelatedWork W2751938426 @default.
- W3217188991 hasRelatedWork W282266550 @default.
- W3217188991 hasRelatedWork W2966278146 @default.
- W3217188991 hasRelatedWork W3217507319 @default.
- W3217188991 hasRelatedWork W4283574631 @default.
- W3217188991 hasVolume "144" @default.
- W3217188991 isParatext "false" @default.
- W3217188991 isRetracted "false" @default.
- W3217188991 magId "3217188991" @default.
- W3217188991 workType "article" @default.